Jeito Capital leads oversubscribed $75 million Series C in Adcendo ApS to Advance its First- and Best-in-class Clinical ADC1 Pipeline in Oncology

Contributed by: Business Wire

Tags

Biotechnology
Pharmaceutical
Health
Oncology
Jeito Capital

More Like This

PR Newswire associated0

Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline

PR Newswire associated0

Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline

PR Newswire associated0

Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates

PR Newswire associated0

Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Business Wire logo

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors

PR Newswire associated0

Adcendo ApS to Participate in Upcoming September Investor Conferences

PR Newswire associated0

Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors

PR Newswire associated0

Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01